The United States FDA has granted Breakthrough Therapy Designation (BTD) to the investigational medication ifinatamab deruxtecan for people with advanced small cell lung cancer (ES-SCLC) who have progressed following platinum-based chemotherapy. The designation denotes regulatory acknowledgement of preliminary clinical data indicating potential improvements over existing treatments for this aggressive cancer. 

ES-SCLC accounts for around 15% of all lung cancer cases worldwide (an estimated 372,000 per year). Following first-line therapy failure, treatment options are severely limited due to fast metastases and poor 5-year survival rates. Patients with ES-SCLC frequently have limited therapy options after disease progression, according to Dr Eliav Barr, Chief Medical Officer at Merck, which is co-developing the medicine with Daiichi Sankyo. 

The FDA's Breakthrough Therapy Designation for ifinatamab deruxtecan is based on Phase 2 findings from the IDeate-Lung01 trial, which included 187 extensively pretreated extensive-stage small cell lung cancer (ES-SCLC) patients from Asia, Europe, and North America. The designation highlights the drug's new mode of action, which targets B7-H3, a protein that is typically overexpressed in SCLC tumours and linked with a poor prognosis but is currently untargeted by any licensed medicines. This experimental antibody-drug combination (ADC) is designed to deliver a strong topoisomerase I inhibitor payload to cancer cells expressing B7-H3. The trial tested two different doses given through an IV (8 mg/kg and 12 mg/kg every three weeks), with the main goal being to see how many patients had a positive response as judged by an independent review that was kept blind. By giving Breakthrough designation, the FDA recognises preliminary clinical evidence indicating a significant improvement over current medicines for this serious ailment with a high unmet medical need, thereby speeding up the drug's development and regulatory review pathway. The entire dataset that underpins this regulatory decision will be released in September 2025 during a late-breaking presentation at the World Conference on Lung Cancer, Daiichi informed. Advances in multi-pass transmembrane proteins display platforms are also helping researchers better study complex membrane protein targets such as B7-H3 during drug development.

While acknowledging the critical need for new ES-SCLC medicines, Dr Ken Takeshita, Global R&D Head at Daiichi Sankyo, emphasised the drug's exploratory nature. Ifinatamab deruxtecan is still not approved globally, and its safety and efficacy have yet to be established. The FDA had already awarded it Orphan Drug designation for SCLC. 

The development takes place against the backdrop of industry concentration on ADCs. Daiichi Sankyo has seven ADCs in clinical development that use two unique platforms. Merck and Daiichi Sankyo extended their ADC partnership in August 2024 to include another candidate (gocatamig). 

The FDA's Breakthrough Therapy Designation emphasises the essential paucity of effective medicines for individuals with advanced small cell lung cancer whose disease worsens after first therapy, revealing a significant public health need. This regulatory acceleration tool reflects a growing realisation of the critical need to speed promising medicines for high-mortality illnesses with few options. Concurrently, the focus on novel targets such as B7-H3 – a biomarker found in aggressive tumours but previously unexplored in approved treatments – represents a significant shift towards investigating biological pathways other than established mutations, potentially expanding future therapeutic landscapes for difficult-to-treat cancers. 

The BTD does not mean that the drug is approved. The final evaluation is based on complete data from ongoing trials (IDeate-Lung01 and IDeate-PanTumor01) that analyse efficacy, safety, and survival advantages. Access and cost consequences remain unclear until future approval. 

The medical community is looking forward to the complete Phase 2 results from the September 2025 meeting, which will allow for a thorough evaluation of the drug's benefit-risk profile in this difficult condition. Additional trials will be required to prove clinical utility.